Confirm histological subtype
Confirm whether you have epithelioid, sarcomatoid, or biphasic mesothelioma — the critical factor for treatment eligibility.
Specialized Unit
Peritoneal Mesothelioma: Surgery and HIPEC
At Quenet-Torrent Institute, we specialize in surgical treatment of peritoneal mesothelioma with complete cytoreduction and HIPEC. In selected patients with epithelioid subtype, this approach offers 5-year survival of 50-70%.
CONTACT SPECIALISTNeed to speak with a specialist?
Complete the form and schedule your appointment to speak directly with the surgeon
-
EXTENSIVE EXPERIENCE +20,000 surgeries performed
-
LATEST TECHNOLOGY in surgical strategy
-
PERSONALIZED CARE First contact within 24/48h
Schedule your consultation with a specialist
What is peritoneal mesothelioma?
Peritoneal mesothelioma is a rare malignant tumor originating from the mesothelial cells that line the peritoneal cavity. It differs from pleural mesothelioma (lung lining) in location, behavior, and prognosis.
There are three main histological subtypes: epithelioid (most common, ~70%, best prognosis), sarcomatoid (worst prognosis), and biphasic (mixed, intermediate prognosis). Subtype is the main determinant of treatment strategy.
While asbestos exposure is a recognized risk factor, 30-50% of cases have no identified cause. BAP1 gene mutations are present in a significant proportion.
In epithelioid cases selected for surgery, cytoreductive surgery with HIPEC achieves median survival of 50-90 months — a dramatic improvement over the approximately 12 months seen without specific surgical treatment.
Why request a second opinion for peritoneal mesothelioma?
This rare tumor requires evaluation by centers with documented experience in this specific condition.
Evaluate surgical candidacy
Assess whether complete cytoreduction is technically and oncologically feasible.
BAP1 and molecular testing
Identify genetic mutations that may influence prognosis and treatment selection.
Immunotherapy integration
Evaluate how immunotherapy (nivolumab + ipilimumab) can be integrated into the overall treatment strategy.
In rare tumors like peritoneal mesothelioma, treatment at a specialized center with documented experience is essential.
How do we treat peritoneal mesothelioma?
Treatment depends critically on histological subtype and is planned in a multidisciplinary committee.
Complete cytoreductive surgery
For epithelioid cases: removal of all visible tumor implants and affected peritoneal surfaces.
HIPEC with cisplatin/mitomycin C
Hyperthermic intraperitoneal chemotherapy immediately after cytoreduction to treat microscopic residual disease.
Immunotherapy
Nivolumab + ipilimumab for unresectable cases or as perioperative treatment in selected candidates.
Systemic chemotherapy
Pemetrexed-based regimens for advanced or unresectable disease.
All cases are discussed in a specialized multidisciplinary tumor board to individualize the optimal treatment sequence.
Our Technology
Technology for treating peritoneal mesothelioma
Specialized diagnostic and surgical technology ensures the best possible outcomes in this rare disease.
Automated HIPEC equipment
Precise thermal and flow control during cisplatin/mitomycin C perfusion.
PET-CT and MRI
Detailed preoperative staging to evaluate disease extent and guide surgical planning.
Molecular pathology
BAP1, NF2, and other relevant molecular markers to guide prognosis and treatment decisions.
Expert mesothelioma pathology
Specialist pathologists with experience in this rare tumor for accurate subtype classification.
WHY CHOOSE US?
Reference center for peritoneal mesothelioma
Quenet-Torrent Institute has extensive experience in this rare tumor and is one of the leading centers in Spain for peritoneal mesothelioma treatment.
Experience in Complex Cases
We specialize in treating advanced and metastatic cancer, using innovative techniques that other teams do not offer.
Comprehensive Multidisciplinary Approach
We form a team around you with surgeons, oncologists, radiologists, nutritionists, and psychologists, all working together for your cure.
Research and Innovation
We stay up to date with the latest scientific advances, allowing us to apply innovative treatments with better results.
State-of-the-Art Technology
We have facilities equipped with the most current medical technology, allowing us to perform high-precision procedures with less impact on the body.
Personalized and Close Care
We care about each patient as a person. We listen, support, and guide every step of the way.
Our Team
Peritoneal mesothelioma specialists
Every physician at Quenet-Torrent Institute is a recognized expert in their field, committed to each patient's well-being.
Dr. François Quenet
Oncological Surgeon
View doctor"Internationally renowned surgeon, expert in gastrointestinal and hepatobiliary tumors. Recognized for his precision in highly difficult surgeries."
Dr. Juan José Torrent
Oncological Surgeon
View doctor"Specialist in gynecological tumors and peritoneal carcinomatosis. A reference in complex and personalized oncological surgery."
Frequently asked questions about peritoneal mesothelioma
Answers to the most common questions about diagnosis, treatment, and prognosis.
Is peritoneal mesothelioma the same as pulmonary mesothelioma?
No. Both originate from mesothelial cells, but in different locations. Peritoneal mesothelioma has a better prognosis thanks to the possibility of surgical treatment.
Is peritoneal mesothelioma always caused by asbestos?
No. Although asbestos is a known risk factor, 30-50% of cases have no documented exposure. BAP1 genetic mutations and other factors are involved in a significant.
What is the life expectancy with peritoneal mesothelioma?
With CRS + HIPEC in epithelioid mesothelioma: median survival 50-90 months and 5-year survival 50-70%. Without specific surgical treatment: median survival approximately.
What histological subtypes exist?
Epithelioid (best prognosis, ~70%), sarcomatoid (worst prognosis, surgery not recommended), and biphasic (intermediate). Subtype is the most critical factor in treatment.
What role does immunotherapy play?
Nivolumab + ipilimumab is now first-line treatment for unresectable mesothelioma. Integration with surgery in resectable cases is being studied in clinical trials.
Where can I receive this treatment safely?
In specialized centers with experience in peritoneal mesothelioma, like Quenet-Torrent Institute, one of the leading centers for this condition in Spain.
Easy Contact
Need to speak with a specialist?
Complete the form and schedule your appointment to speak directly with the surgeon.